A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer

Xequel Bio

Status and phase: Terminated; Phase 3

Conditions: Diabetic Foot Ulcers

Treatments: Other: Vehicle gel; Drug: Granexin gel

Study type: Interventional

Funder types: Other

Identifiers

NCT02667327

2015-DFU-301

Details and patient eligibility

About

The purpose of this study is to determine whether Granexin gel is safe and effective in the treatment of diabetic foot ulcers.

Full description

DFU patients will undergo a one week screening period and those with changes in ulcer size of less than 30% will be eligible for randomization providing all other criteria are met. Participants enrolled in the study will receive treatment based on randomization into 1 of 3 treatment arms for up to 12 weeks. The participants will have an additional 12 week follow-up period beyond the treatment period to assess durability of wound closure.

Enrollment: 124 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Both male and female participants may participate in the study.

To be eligible for entry into this study, a patient must meet all of the following Inclusion criteria:

1. Age 18 years or older

2. Established diagnosis of diabetes mellitus (type I or II)

3. Glycosylated hemoglobin (HbA1c) value < 12.0% at the screening visit

4. Diagnosis of neuropathic foot ulcer by 10g monofilament test, tuning fork (128 Hz), or cotton wisp

5. Designated foot ulcer meets the following criteria at both the screening and baseline visits:

   1. Present for at least 4 weeks
   2. Full-thickness cutaneous ulcer below the ankle surface
   3. University of Texas grade A1
   4. Wound area (after debridement) 1 to 40.0 cm2
   5. Viable, granulating wound (investigator discretion)

6. Ankle brachial index ≤ 0.7 at both the screening and baseline visits. If the ABI is >1.30, one of the following confirmatory tests must be performed for the patient to be considered eligible:

   1. Does Not have a monophonic or biphasic flow (with the loss of reverse flow) in the artery of the foot with the target ulcer via doppler waveform analysis of the dorsalis pedis and posterior tibial arteries, as determined by standard practices of the investigator and the site.
   2. Transcutaneous oxygen pressure (TcPO2) at the foot >40 mmHg

   Additionally, patients must meet all other protocol-defined eligibility criteria.

7. Signed informed consent

8. Female patients of childbearing potential must have a negative pregnancy test at screening and must agree to use hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence throughout until 2 weeks after the last administration of investigational product. Male patients must also agree to use contraception such as a condom.

Exclusion criteria

Patients will not be eligible for enrollment in the study if they meet any of the exclusion criterial listed below:

1. Change (decrease or increase) in size of the designated target ulcer by ≥ 30% during the 7-day screening period

2. Cannot tolerate the off-loading methods or cannot comply with study related procedures

3. Has an ulcer that meets any of the following criteria:

   1. Shows signs of severe clinical infection, defined as pus oozing from the ulcer site
   2. Requires surgical debridement
   3. Is positive for β-hemolytic streptococci upon culture performed prior to screening debridement procedure
   4. Has > 50% slough, significant necrotic tissue, bone, tendon, or capsule exposure
   5. Is highly exuding (i.e., requires daily change of dressing)

4. Requires total contact cast

5. Ankle brachial pressure index < 0.7

6. Has a local or systemic infection or local lymphangitis ≥ 0.5 cm

7. Has any 1 of the following (only 1 of the 2 tests is required):

   1. A monophasic or biphasic flow (with loss of reverse flow) in the artery of the foot with the target ulcer via doppler waveform analysis of the dorsalis pedis and posterior tibial arteries
   2. Transcutaneous oxygen pressure (TcPO2) at the foot <40 mgHg

8. Presence of active malignant or benign tumor of any kind, (with the exception to nonmelanoma skin cancer as per investigator's discretion)

9. Congestive heart failure (New York Heart Association class II-IV)

10. Coronary heart disease with ST segment elevation myocardial infarction or coronary artery bypass graft or percutaneous transluminal coronary angioplasty within the last 6 months

11. Active osteomyelitis of the foot with the target ulcer detected by x-ray, CT scan, or MRI

12. Active connective tissue disease

13. Acute or chronic Charcot's neuro-arthropathy as determined by clinical and/or radiographic examination

14. Active treatment with systemic corticosteroids or topical corticosteroids (for treatment of the target ulcer or any area of the foot). This does not include inhaled corticosteroids used for conditions other than treating the target ulcer or any area of the foot. Wash out period for systemic corticosteroids is 14 days for inclusion in this study. Wash out period for topical corticosteroids (for treatment of the target ulcer or any area of the foot) is 14 days for inclusion in the study)

15. Active treatment with systemic antibiotics (wash out period for systemic antibiotics is 7 days for the inclusion in the study)

16. Previous or current radiation therapy to the distal lower extremity or likelihood to receive this therapy during study participation

17. Pregnant or nursing mothers

18. Uncontrolled anemia (hemoglobin < 10 g/dL in females and < 12 g/dL in males)

19. Estimated glomerular filtration rate < 25 mL/min

20. Poor nutritional status, defined as an albumin < 25 g/L (< 2,500 mg/dl)

21. Significant peripheral edema as per investigator's discretion

22. Known inability or unavailability of a patient to complete required study visits during study participation

23. A psychiatric condition (e.g., suicidal ideation) or chronic alcohol or drug abuse problem, determined from the patient's medical history, which, in the opinion of the investigator, may pose a threat to patient compliance

24. Use of a platelet-derived growth factor within 28 days before screening

25. Use of any investigational drug or therapy within 28 days before screening

26. Has any other factor which may, in the opinion of the investigator, compromise participation and/or follow-up in the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

124 participants in 3 patient groups, including a placebo group

Granexin gel plus Standard of Care

Active Comparator group

Description:

Granexin gel is comprised of 100 μM aCT1 peptide plus hydroxyethyl cellulose.

Treatment:

Drug: Granexin gel

Vehicle gel plus Standard of Care

Placebo Comparator group

Description:

Vehicle gel is hydroxyethyl cellulose without active pharmaceutical ingredient.

Treatment:

Other: Vehicle gel

Standard of Care

No Intervention group

Description:

Standard of Care includes cleaning and irrigating ulcer, non-surgical debridement, pain management, ulcer dressing, off-loading, and nutritional assessment.